CALGARY, AB — December 23, 2025 — Leads & Copy — Nanalysis Scientific Corp. has closed the first tranche of its non-brokered private placement, issuing 16,526,283 units at $0.15 per unit, raising approximately $2.5 million.
The company (TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1) will use the net proceeds for debt reduction, as previously disclosed in its December 8, 2025, press release. Nanalysis expects to close the second tranche of the offering in January 2026.
Due to strong investor demand, Nanalysis has increased the size of the offering and will now issue up to an additional 23,333,333 units at $0.15 per unit, potentially raising up to $3,500,000. The upsize of the offering remains subject to the approval of the TSX Venture Exchange. These additional proceeds will also be used for debt reduction and magnet inventory purchases.
The company may pay a finder’s fee of up to 5% on parts of the proceeds from purchasers introduced to the company by registered investment advisors, payable in cash.
Each unit consists of one common share and one-half of one common share purchase warrant. Each whole warrant allows the holder to acquire one additional share at an exercise price of $0.20 per share, up to 4:00 p.m. (Calgary time) on or before the date that is two years from the applicable closing date. If the closing price of the shares on the TSX Venture Exchange equals or exceeds $0.30 for any 10 consecutive trading days, the company may accelerate the expiry date of the warrants to 30 days after notice is provided.
In connection with the first tranche, Nanalysis paid $1,500 in cash commission finder’s fees to Haywood Securities Inc. The first tranche remains subject to final acceptance by the TSX Venture Exchange. All securities issued under the first tranche are subject to a statutory hold period of four months and one day from the date of issuance, in accordance with applicable securities laws. The company anticipates completing additional tranches, subject to market conditions and regulatory approvals.
Sean Krakiwsky, an insider of Nanalysis Scientific Corp., subscribed for $52,500 under the first tranche, which constitutes a “related party transaction” under Multilateral Instrument 61-101. The company is relying on exemptions from formal valuation and minority shareholder approval requirements because the insider’s participation does not exceed 25% of the company’s market capitalization.
Nanalysis Scientific Corp. develops and manufactures portable Nuclear Magnetic Resonance (NMR) spectrometers used in pharma, biotech, energy, food, materials, security industries, academic, and government labs. The company also operates a services division that maintains its own products and third-party imaging equipment, supported by a $160 million long-term contract with the Canadian Air Transport Security Authority (CATSA) to maintain security scanners at over 80 Canadian airports.
Source: Nanalysis Scientific Corp.
